“Lonza’s sales in 2025 benefited from robust momentum in the Mammalian, Bioconjugates, Small Molecules, Drug Product and Bioscience Technology Platforms, and was further supported by a higher than expected contribution of the Vacaville site,” the company noted. Business highlights for the company included an increased number of drug product agreements and progress at the Vacaville site. “Lonza continued to expand renewable sourcing across all key regions,” the release reads. “Looking ahead, Lonza plans to further expand its asset base, leveraging its strong track record of building, acquiring, and operating assets worldwide. The high‑quality, large‑scale capacities in Vacaville, together with the expertise of its local team, significantly strengthen Lonza’s global mammalian offering.”